Klaus Ehrlich
Aventis Pharma
6 Papers
56 Citations
Klaus Ehrlich is an academic researcher from Aventis Pharma. The author has contributed to research in topics: Streptomyces & Lipase. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Cyclipostins, novel hormone-sensitive lipase inhibitors from Streptomyces sp. DSM 13381. II. Isolation, structure elucidation and biological properties.
Laszlo Vertesy,Bernd Beck,Mark Brönstrup,Klaus Ehrlich,Michael Kurz,Günter Müller,Dietmar Schummer,Gerhard Seibert +7 more
TL;DR: Ten inhibitors of HSL, termed cyclipostins, have been isolated from the mycelium of this microorganism and a further nine related compounds detected and have physicochemical properties similar to those of triglycerides.
Pluraflavins, potent antitumor antibiotics from Saccharothrix sp. DSM 12931.
Laszlo Vertesy,Barbone Francis P,Elizabeth Cashmen,Heinrich Decker,Klaus Ehrlich,Jordan Birgit Dr,Martin Knauf,Dietmar Schummer,Marian Paul Segeth,Joachim Wink,Gerhard Seibert +10 more
TL;DR: The outstanding biological characteristic of pluraflavin A is its powerful, organ-dependent cytostatic action: the IC50 in the colon carcinoma proliferation assay is in the subnanomolar range.
23
Patent
Cyclipostins, process for their preparation and use thereof
Laszlo Vertesy,Klaus Ehrlich,Michael Kurz,Joachim Wink +3 more
- 22 Jun 2001
TL;DR: In this article, the authors describe a process for the preparation of cyclipostins, the microorganism HAG 004107 (DSM 13381), and their use as pharmaceuticals, in particular as inhibitors of lipases.
4
Patent
Coniosulfides and their derivatives, processes for preparing them, and their use as pharmaceuticals
Laszlo Vertesy,Klaus Ehrlich,Michael Kurz,Marian Paul Segeth,Luigi Toti +4 more
- 19 Sep 2002
TL;DR: In this article, the authors describe a process for preparing compounds of the formula (I) and their use as pharmaceuticals (II) for the treatment and prophylaxis of degenerative neuropathics or of Alzheimer's disease.
4